Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.64 |
| ▸ | GRM8 | O00222 | 1/20 | 0.64 |
| ▸ | GRM6 | O15303 | 1/20 | 0.64 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.64 |
| ▸ | GSR | P00390 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 1/20 | 0.64 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.64 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.64 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.64 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.64 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.64 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.64 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.64 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30973852 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL30973850 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1769459 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL12210209 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL9223132 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL9225173 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL236257 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL6853383 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL22750154 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL30973851 | 1.00 | FOLH1 (0.64) | FOLH1GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | claimed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | claimed |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2024-11-21 | — | — | US | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4648849-A1 | NMU RECEPTOR 2 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-12427187-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| US-12214059-B2 | Cleavable radioligands for targeting cell surface receptors and uses thereof | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2025-02-04 | — | — | US | disclosed |
| WO-2024245407-A1 | CONJUGATES AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024133382-A1 | GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023097038-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3980052-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2020247297-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20190274334-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2017181062-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-0268377-B1 | GLUTAMIC ACID DERIVATIVES, PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-18 | — | — | EP | disclosed |
| EP-0268377-A2 | Glutamic acid derivatives, processes and intermediates for their preparation and pharmaceutical formulations containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, GPR18 | FOLH1 547/4885GRM8 151/4885GRM6 248/4885 |
| US-12427187-B2 | Glucose-responsive insulin conjugates | GPR119, IRS1, INSR | FOLH1 410/4885GRM8 468/4885GRM6 189/4885 |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | FOLH1 22/4885GRM8 906/4885GRM6 1212/4885 |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, IRS1, INSR | FOLH1 410/4885GRM8 468/4885GRM6 189/4885 |
| US-12214059-B2 | Cleavable radioligands for targeting cell surface receptors and uses thereof | ASGR1, GNRHR, SCTR | FOLH1 22/4885GRM8 906/4885GRM6 1212/4885 |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | FOLH1 22/4885GRM8 906/4885GRM6 1212/4885 |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | GLP1R, GIPR, NPY1R | FOLH1 479/4885GRM8 962/4885GRM6 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.